Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Mehmet A. Sendur, MD, Ankara Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey, discusses the treatment of BRCA1 and BRCA2 mutated metastatic breast cancer using PARP inhibitors, as well as commenting on the use of sacituzumab govetican for treatment of triple-negative breast cancer. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.